Drug profile · INN
oxyphencyclimine hydrochloride
DARICON
oxyphencyclimine hydrochloride (DARICON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — oxyphencyclimine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
oxyphencyclimine hydrochloride (DARICON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is oxyphencyclimine hydrochloride?
oxyphencyclimine hydrochloride (DARICON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for oxyphencyclimine hydrochloride?
DARICON is a marketed brand name for oxyphencyclimine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxyphencyclimine hydrochloride?
oxyphencyclimine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.